These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 572694)

  • 1. Mixed agonist-antagonist opiates and physical dependence.
    Jacob JJ; Michaud GM; Tremblay EC
    Br J Clin Pharmacol; 1979; 7 Suppl 3(Suppl 3):291S-296S. PubMed ID: 572694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphrine: demonstration of physical dependence liability.
    Dum J; Bläsig J; Herz A
    Eur J Pharmacol; 1981 Mar; 70(3):293-300. PubMed ID: 6262095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
    Stinus L; Cador M; Zorrilla EP; Koob GF
    Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitution and primary dependence studies in animals.
    Woods JH; Gmerek DE
    Drug Alcohol Depend; 1985 Feb; 14(3-4):233-47. PubMed ID: 4039649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.
    Cowan A; Lewis JW; Macfarlane IR
    Br J Pharmacol; 1977 Aug; 60(4):537-45. PubMed ID: 409448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical dependence induced by opiate partial agonists in the rat.
    McCarthy PS; Howlett GJ
    Neuropeptides; 1984 Dec; 5(1-3):11-4. PubMed ID: 6152317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Opioid tolerance and dependence--pharmacological aspects].
    Jaba IM; Luncanu I; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):444-50. PubMed ID: 12092171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse liability studies of opioid agonist-antagonists in humans.
    Preston KL; Jasinski DR
    Drug Alcohol Depend; 1991 Jun; 28(1):49-82. PubMed ID: 1884671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side-effects of mixed agonist-antagonist analgesics used in sequential anaesthesia.
    Devaux C; Schoepffler P; Gauthier-Lafaye JP
    Br J Clin Pharmacol; 1979; 7 Suppl 3(Suppl 3):323S-326S. PubMed ID: 465294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
    Jasinski DR; Pevnick JS; Griffith JD
    Arch Gen Psychiatry; 1978 Apr; 35(4):501-16. PubMed ID: 215096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1979 Feb; 17(2):81-110. PubMed ID: 378645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid agonist-antagonist drugs in acute and chronic pain states.
    Hoskin PJ; Hanks GW
    Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonist treatment of opioid withdrawal translational low dose approach.
    Mannelli P; Gottheil E; Van Bockstaele EJ
    J Addict Dis; 2006; 25(2):1-8. PubMed ID: 16785213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic.
    Pircio AW; Gylys JA; Cavanagh RL; Buyniski JP; Bierwagen ME
    Arch Int Pharmacodyn Ther; 1976 Apr; 220(2):231-57. PubMed ID: 60089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects and analgesic efficacy of the agonist-antagonist opioids.
    Zola EM; McLeod DC
    Drug Intell Clin Pharm; 1983 Jun; 17(6):411-7. PubMed ID: 6861632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.